Not Signed In - Peregrine's Licensee Initiates Phase I Clinical Trial In Europe With Novel Tumor Necrosis Therapy Cancer Agent
Fri, 23 Feb 2007 08:00 AM EST
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that one of its licensees has initiated European clinical trials of a novel anti-cancer agent developed with technology licensed from Peregrine. [click link for full article] ...
Related Topics
- Clinical Trials
- Cancer
- Avascular Necrosis
- Agent Orange
- Pancreatic Cancer
- Benign Tumors
- Chemical Agents
- Brain Tumor
- Cancer Alternative Therapy
- Tumor Markers
- Tarceva
- Cancer Radiation Therapy
- Ovarian Cancer
- Prostate Cancer
- Bevacizumab Injection
- Radiation Therapy
- Chelation therapy
- Benign Tumor
- Trastuzumab
- Natural therapy
email this page
print this page
bookmark this page
feedback on this page
